Search results for " 2020"
Article
Enhancing Resins Addresses Purification Concerns
29, 2020.
3. N. El-Hajjami, “Plasmid DNA Production for Cell and Gene Therapy,” Cell Culture DISH, Nov. 30, 2020.
4. M. Urabe, et al., Molecular Therapy 13 (4) 823–828 (2006).
Ab…
Article
Maximum Output Starts with Optimized Upstream Processing
“Prior to the pandemic, large investments in capacity were being put in place with the likes of Cobra Biologics in the UK completing its viral vector production expansion in 2020 and with other signif…
Article
Genetic Vaccine Platforms Demonstrate Their Potential
This situation has started to change with FDA granting Emergency Use Authorizations to the mRNA vaccines from Pfizer-BioNTech and Moderna for COVID-19 in late 2020 and approval for the viral-vector va…
Article
Reimagining Affordable Biosimilars
Advances in preclinical development play a crucial role in reducing cost for developing biosimilars.
By Anurag S. Rathore, Narendra Chirmule, and Himanshu Malani
Drug development is …
Article
Improving Upstream Predictability
One showcase will be Amgen’s facility in West Greenwich, RI, construction of which is expected to be completed in 2020 (1). Leveraging PAT and sensor technology, it will feature a modular design and u…
Article
ADC Development Robust Despite Lackluster Performance
The company plans to submit regulatory filings for these indications in 2020 or later (11).
In addition to these combination-use clinical trials, Roche is also conducting two Phase III clinical…
Article
Biopharma in 2016: Higher Quality Drugs, Less Expensive Manufacturing
Analysts expect the worldwide biosimilars market to reach $25 billion to $35 billion by 2020.2 Many experts recall Trump’s criticism of high drug prices and expect that he will try to control pricing …
Article
Framing Biopharma Success in 2016
Corporate restructurings, regulatory initiatives, and biosimilars will shape biopharma development in 2016.
By Rita C. Peters
The US biopharmaceutical industry turned a new page in 2015 when…
Article
Bracing for a Future Wave of Advanced Therapies
With the help of recent investor interest, progression of advanced therapy medicinal products (ATMPs) in the clinical space continues to move forward. Buoyed by the regulatory approval of sever…
Article
Report from the 12th Plasma Product Biotechnology Forum
One of the consequences during the lockdown beginning in 2020 was an acute decline in plasma collection, due to donors reluctant to leave their homes, plus also negative effects from the alterations t…